Pozen Inc: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Pozen, founded in 1996, is a pharmaceutical company focused primarily on developing products for the treatment of acute and chronic pain and other pain-related conditions. The company's main concept is to develop combination pharmaceutical products that combine two active ingredients to enhance patient compliance and improve either efficacy or safety.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Pozen is a pharmaceutical company developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions. Trexima, the company's most advanced product candidate, is under FDA review. Trexima is developed by the company in collaboration with GSK.

    The company has also entered into a collaborative agreement with AstraZeneca. The company generated all of its revenues through license, collaboration, milestone and upfront payments. It did not generate revenues in 2002, and its revenues increased from $4 million to $14 million between 2003 and 2006.

    The company's revenues are forecasted to witness an absolute growth of +62 million between 2006 and 2010. Total revenues are estimated to increase at a CAGR of 53% during 2006-2010, from $14 million to $76 million. Royalties on Trexima sales will be the major contributor to the company's revenue growth during the period.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: pozen lornoxicam trexima r number ingredients valuechainanalysisforastrazeneca suppliers employees pozenrevenuesinsegment

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.